Q3 EPS Estimate for Monopar Therapeutics Cut by Analyst

Key Points

• HC Wainwright cut Monopar Therapeutics’ Q3 2026 EPS estimate to a loss of $0.90 per share from $0.79, while maintaining a Buy rating and $125 price target. Its forecasts project continued losses through FY2027 before a return to positive earnings in FY2028.
• Analyst sentiment remains mixed: Barclays raised its target to $128 and retained an Overweight rating, while Cantor Fitzgerald downgraded the stock to Neutral and Wall Street Zen cut it to Sell. MarketBeat’s consensus rating is Moderate Buy with an average price target of $117.42.
• Monopar recently reported a quarterly loss of $0.62 per share, beating the consensus estimate of a $0.64 loss. The stock opened at $113.04, near its 12-month high of $124.82, with a market capitalization of approximately $758.5 million.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Monopar Therapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.90) per share for the quarter, down from their prior forecast of ($0.79). HC Wainwright has a "Buy" rating and a $125.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Monopar Therapeutics' Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at $0.87 EPS.

Several other brokerages also recently weighed in on MNPR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Barclays reissued an "overweight" rating and issued a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday. Wall Street Zen cut shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Finally, Cantor Fitzgerald downgraded shares of Monopar Therapeutics from an "overweight" rating to a "neutral" rating and upped their target price for the stock from $109.00 to $119.00 in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $117.42.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $113.04 on Monday. The firm has a 50 day moving average of $96.11 and a 200 day moving average of $71.53. The firm has a market capitalization of $758.50 million, a price-to-earnings ratio of -52.09 and a beta of 1.47. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets increased its holdings in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after acquiring an additional 349 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Monopar Therapeutics in the 4th quarter valued at $65,000. Caitong International Asset Management Co. Ltd purchased a new stake in Monopar Therapeutics in the 4th quarter worth $86,000. Finally, JPMorgan Chase & Co. lifted its stake in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. Institutional investors own 1.83% of the company's stock.

Key Stories Impacting Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $125 price target, modestly above the recent trading level. Its published forecasts anticipate a transition from losses to positive earnings by FY2028, with additional long-term estimates extending into FY2029. What is HC Wainwright's Forecast for MNPR FY2029 Earnings?
• Neutral Sentiment: Analyst coverage highlighted Monopar among healthcare companies, but the supplied report does not identify a new price target or specific fundamental catalyst. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across FY2026 through FY2028: FY2026 to a loss of $3.07 per share, FY2027 to a loss of $1.46, and FY2028 earnings to $0.87. Quarterly estimates were also lowered, including Q3 2026 to a loss of $0.90 and Q4 2026 to a loss of $1.08, signaling expectations for weaker near-term profitability.
• Negative Sentiment: Zacks Research downgraded Monopar from “Strong Buy” to “Hold,” while Wall Street Zen lowered the stock to “Sell.” These rating changes may weigh on sentiment, particularly after the stock’s strong run and elevated valuation. Monopar Therapeutics Lowered to Sell Rating

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source